Advertisement

Psychopharmacology

, Volume 95, Issue 3, pp 298–302 | Cite as

The effects of chronic antidepressant treatment in an animal model of anxiety

  • Shari R. Bodnoff
  • Barbara Suranyi-Cadotte
  • David H. Aitken
  • Remi Quirion
  • Michael J. Meaney
Original Investigations

Abstract

We have examined the anxiolytic activity of acute and chronic antidepressant treatment in an animal model of anxiety involving novelty-suppressed feeding. Rats were food deprived for 48 h, placed into a novel environment containing food, and the latency to begin eating was recorded. Chronic (21 days), but not acute injections of desipramine (DMI; 10 mg/kg) and amitriptyline (AMI; 10 mg/kg) significantly reduced the latency to begin eating compared to controls, but the percentage decrease was not as great as that seen with either acute or chronic treatment with diazepam (2 mg/kg) or adinazolam (20 mg/kg). A time course study indicated that at least 2 weeks of treatment was necessary to observe a significant anxiolytic effect of antidepressants. The anxiolytic effect of the antidepressants was specific to the novel environment, as 2 weeks of treatment with either diazepam or DMI did not influence the latency to begin eating in the home cage. Finally, a single dose of the central benzodiazepine receptor antagonist, Ro15-1788 (20 mg/kg), given 15 min prior to testing, did not block the anxiolytic effects of chronic DMI, while it completely eliminated the effect of chronic diazepam treatment. These data suggest that antidepressants acquire anxiolytic properties following chronic administration and that this effect appears to be independent of the benzodiazepine receptor system.

Key words

Anxiety Depression Novelty-suppressed feeding Diazepam Adinazolam Desipramine Amitriptyline Ro15-1788 Rat 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aprison MH, Ferster CB (1961) Neurochemical correlates of behavior: Correlation of brain monoamine oxidase activity with behavioral changes after iproniazid and 5-hydroxytryptophan. J Neurochem 6:350–357Google Scholar
  2. Ashton H (1984) Benzodiazepine withdrawal: An unfinished story. Br Med J 288:1135–1140Google Scholar
  3. Ballenger JC, Sheehan D, Jacobsen G (1977) Anti-depressant treatment of severe phobic anxiety. Paper read before the 130th annual meeting of the American Psychiatric Association, TorontoGoogle Scholar
  4. Banarjee SP, Kung LS, Riggi SJ, Chandra SK (1977) Development of β-adrenergic receptor subsensitivity by anti-depressants. Nature 268:455–456Google Scholar
  5. Barbaccia ML, Ravizza L, Costa E (1986) Maprotiline: an antidepressant with an unusual pharmacological profile. J Pharmacol Exp Ther 236:307–312Google Scholar
  6. Bouthillier A, Montigny C de (1987) Long-term anti-depressant treatment reduces neuronal responsiveness to flurazepam: an electrophysiological study in the rat. Neurosci Lett 73:271–275Google Scholar
  7. Britton DR, Thatcher-Britton R (1981) A sensitive open-field measure of anxiolytic drug activity. Pharmacol Biochem Behav 15:577–582Google Scholar
  8. Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K (1986) Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 315:854–859Google Scholar
  9. Charney DS, Menkes DB, Heninger GR (1981) Receptor sensitivity and the mechanism of action of antidepressant treatment. Arch Gen Psychiatry 38:1161–1179Google Scholar
  10. Cole SO (1983) Combined effects of chlordiazepoxide treatment and food deprivation on concurrent measures of feeding and activity. Pharmacol Biochem Behav 18:369–372Google Scholar
  11. Cooper SJ (1980) Effects of chlordiazepoxide and diazepam on feeding performance in a food preference test. Psychopharmacology 69:73–78Google Scholar
  12. Cooper SJ (1985) Bidirectional control of palatable food consumption through a common benzodiazepine receptor: Theory and evidence. Brain Res Bull 15:397–410Google Scholar
  13. Cooper SJ, Yerbury RE (1986) Midazolam-induced hyperphagia and FG-7142-induced anorexia: behavioral characteristics in the rat. Pharmacol Biochem Behav 25:99–106Google Scholar
  14. Davis M, Redmond E, Baraban JM (1979) Noradrenergic agonists and antagonists: effect on conditioned fear as measured by the potentiated startle paradigm. Psychopharmacology 65:111–118Google Scholar
  15. File SE (1986) Aversive and appetitive properties of anxiogenic and anxiolytic agents. Behav Brain Res 21:189–194Google Scholar
  16. File SE, Tucker JC (1986) Behavioral consequences of antidepressant treatment in rodents. Neurosci Biobehav Rev 10:123–134Google Scholar
  17. Hoehn-Saric R (1982) Neurotransmitters in anxiety. Arch Gen Psychiatry 92:735–742Google Scholar
  18. Hollister LE (1978) Clinical pharmacology of psychotherapeutic drugs. Churchill Livingstone, New YorkGoogle Scholar
  19. Kahn RJ, McNair D, Lipman RS, Covi L, Rickels K, Downing R, Fisher S, Frankenthaler LM (1986) Imipramine and chlordiazepoxide in depressive and anxiety disorders. efficacy in anxious outpatients. Arch Gen Psychiatry 43:79–85Google Scholar
  20. Kelly D (1973) Progress in anxiety states. Proc R Soc Med 66:252–255Google Scholar
  21. Kilts CD, Commissaris RL, Rech RH (1981) Comparison of anti-conflict drug effects in three experimental models of anxiety. Psychopharmacology 74:290–296Google Scholar
  22. Montigny C de, Aghajanian GK (1978) Tricyclic anti-depressants: long term treatment increases responsivity of rat forebrain to serotonin. Science 202:1303–1306Google Scholar
  23. Muskin PR, Fyer AJ (1981) Treatment of panic disorder. J Clin Psychopharmacol 1:81–90Google Scholar
  24. Owens RT, Tyrer P (1983) Benzodiazepine dependence: a review of the evidence. Drugs 25:385–398Google Scholar
  25. Peroutka SJ, Snyder SH (1980) Chronic antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science 210:88–90Google Scholar
  26. Poschel BPH (1971) A simple and specific screen for benzodiazepine-like drugs. Psychopharmacologia 19:193–198Google Scholar
  27. Russell GFM, DeSilva P (1983) Observations in the relationship between anxiety and depressive symptoms during the course of depressive illness. Br J Clin Pharmacol 15:1475–1535Google Scholar
  28. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509–522Google Scholar
  29. Schuckit MA, Feighner JP (1972) Safety of high dose tricyclic antidepressant therapy. Am J Psychiatry 128:140–143Google Scholar
  30. Sellinger-Barnette MS, Mendels J, Frazer A (1980) The effect of psychoactive drugs on β-adrenergic receptor binding sites in rat brain. Neuropharmacology 19:447–454Google Scholar
  31. Shephard RA, Broadhurst PL (1982) Hyponeophagia an arousal in rats: effects of diazepam, 5-methoxy-N,N-dimethyltryptamine, d-amphetamine and food deprivation. Psychopharmacology 78:368–372Google Scholar
  32. Stein L, Berger BD (1973) Anti-anxiety action of benzodiazepines: decrease in activity of serotonin neurons in the punishment system. In: Garattini S, Mussini E, Randall LO (eds) The benzodiazepines. Raven Press, New York, pp 299–326Google Scholar
  33. Sulser F, Vetulani J, Mobley PL (1978) Mode of action of antidepressant drugs. Biochem Pharmacol 27:257–261Google Scholar
  34. Suranyi-Cadotte BE, Dam TV, Quirion R (1984) Antidepressant-anxiolytic interaction: Decreased density of benzodiazepine receptors in rat brain following chronic administration of antidepressants. Eur J Pharmacol 106:673–675Google Scholar
  35. Suranyi-Cadotte BE, Meaney MJ, Bodnoff SR, Lafaille F, Dalpe M, Quirion R (1987) Visualization of benzodiazepine and T-butylbicyclophosphorothionate [(35S)TBPS] binding sites following anxiolytic and anti-depressant treatment. Abstract Presented at the 17th annual meeting of the Society for Neuroscience, New OrleansGoogle Scholar
  36. Widlocher D, Lecrubier Y, LeGoc Y (1983) The place of anxiety in depressive symptomatology. Br J Clin Pharmacol [Suppl] 15:171S–179SGoogle Scholar
  37. Wise CD, Berger BD, Stein L (1972) Benzodiazepines: Anxiety-reducing activity by reduction of serotonin turnover in the brain. Science 77:180–183Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • Shari R. Bodnoff
    • 1
    • 2
  • Barbara Suranyi-Cadotte
    • 1
  • David H. Aitken
    • 1
  • Remi Quirion
    • 1
  • Michael J. Meaney
    • 1
  1. 1.Douglas Hospital Research Center, Department of Psychiatry, Lehmann Pavillion, Faculty of MedicineMcGill UniversityMontrealCanada
  2. 2.Department of PsychologyConcordia UniversityMontrealCanada

Personalised recommendations